AAD 2022: Novel Cream May Aid Repigmentation in Vitiligo on Face, Body
Phase 3 studies show improvement through 52 weeks with ruxolitinib, which was generally well tolerated
Sign in to PracticeUpdate
Only registered members have full access to PracticeUpdate content.